With precision medicines accounting for at least 25% of FDA approvals in the last 7 years, personalized healthcare is far from niche. Personalization is one of the foundations of modern healthcare, advancing how we realize better outcomes for patients and society.
Related forces like value-based care and patient empowerment are bolstering the movement towards personalization. At the same time, the COVID-19 pandemic has disrupted the health landscape—illuminating inequities, spurring technological innovation, and further elevating the role of human behavior in health.
Bringing together a wide array of stakeholders—from the pharmaceutical and diagnostic industry to providers, payers, patients, and clinicians—is crucial for exchanging perspectives and ideas in this changing landscape. This is just what the Personalized Medicine Coalition did at its 16th annual conference, “From an Enterprise to an Era,” in May.
Read on for our key takeaways from the rich conversations at the conference and learn what they mean for innovators working to continue advancing personalized healthcare.
Fill out the form below to read the full article.